Search results for "Nephrogenic Fibrosing Dermopathy"

showing 3 items of 3 documents

[Gadolinium-containing contrast agents: Gadoterat-meglumine is safe in patients with chronic renal failure].

2014

Objective To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients. Methods Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at −15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between base…

MaleDrug-Related Side Effects and Adverse ReactionsContrast MediaAcute Kidney InjuryMeglumine gadoterateMagnetic Resonance ImagingNephrogenic Fibrosing DermopathyHeterocyclic CompoundsGd-DOTANephrogenic systemic fibrosisOrganometallic CompoundsHumansFemaleRenal Insufficiency ChronicGadolinium-based contrast agent-induced nephropathyMRIRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).

2012

To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients.Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at -15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between baseline and 72 ± 24 h …

Malemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsContrast MediaNephrogenic Fibrosing DermopathyHeterocyclic CompoundsRisk FactorsOrganometallic CompoundsPrevalenceMedicineHumansRadiology Nuclear Medicine and imagingRenal Insufficiency ChronicneoplasmsNeuroradiologyAgedmedicine.diagnostic_testMegluminebusiness.industryAcute kidney injuryMagnetic resonance imagingInterventional radiologyGeneral MedicineAcute Kidney Injurymedicine.diseaseMagnetic Resonance ImagingEuropeTreatment OutcomeRadiology Nuclear Medicine and imagingNephrogenic systemic fibrosisAngiographyFemaleRadiologybusinessmedicine.drugKidney diseaseEuropean radiology
researchProduct

Nephrogenic systemic fibrosis--a rapidly progressive disabling disease with limited therapeutic options.

2009

Background Nephrogenic systemic fibrosis (NSF) affects some patients on dialysis after gadolinium contrast agent–enhanced magnetic resonance imaging. It is characterized by progressive skin fibrosis of the extremities, sometimes including the trunk and internal organs. Methods The clinical course of 10 patients with biopsy-proven NSF was analyzed retrospectively with regard to gadolinium exposition, disease onset, and progression of NSF with special emphasis on physical mobility and impact of different therapeutic approaches. Results Despite physiotherapy and different additional therapeutic approaches (eg, immunosuppression, ultraviolet A-1 phototherapy, or extracorporal photopheresis) all…

Nephrogenic Fibrosing DermopathyAdultmedicine.medical_specialtymedicine.medical_treatmentBiopsyGadoliniumDermatologyHydronephrosisNephrectomyEnd stage renal diseaseNephrogenic Fibrosing DermopathyPhotopheresisFibrosisRenal DialysismedicineHumansKidney transplantationDialysisbusiness.industrymedicine.diseaseMagnetic Resonance ImagingSurgeryNephrogenic systemic fibrosisDisease ProgressionFemalebusinessKidney diseaseJournal of the American Academy of Dermatology
researchProduct